PDE4A and chronic obstructive pulmonary disease: Tanimilast (international non-proprietary name of CHF6001) is a novel and potent selective inhaled PDE4 inhibitor developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD) [6].